Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks halts development of cancer drug after trial setback
06:18am, Tuesday, 02'nd Sep 2025
Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
06:00am, Tuesday, 02'nd Sep 2025
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 19'th Aug 2025
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 12'th Aug 2025
Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a t
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
06:00am, Monday, 11'th Aug 2025
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript
04:33pm, Friday, 08'th Aug 2025
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kenneth H. Galbraith - Chairman of the Board, CEO & President Leone D.
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
07:35pm, Thursday, 07'th Aug 2025
Zymeworks Inc. (ZYME) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to a loss of $0.26 per share a year ago.
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
11:00am, Friday, 18'th Jul 2025
Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
06:00am, Thursday, 17'th Jul 2025
VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
01:00pm, Friday, 20'th Jun 2025
Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
04:34pm, Thursday, 12'th Jun 2025
Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Ph
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
11:01am, Wednesday, 04'th Jun 2025
The consensus price target hints at a 76.7% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
